Company Overview
Alaunos Therapeutics, Inc. operates as a clinical-stage oncology-focused cell therapy company that is currently developing small molecules designed to treat obesity and other metabolic disorders. The firm specifically focuses on creating an oral obesity compound intended to address the limitations associated with injectable GLP-1 receptor agonists, such as issues regarding the preservation of lean muscle mass. This entity functions within the Healthcare sector, specifically inside the Biotechnology industry, which generally implies a focus on long-term research and development with high regulatory hurdles. The company's market capitalization is valued at $6.65M, while its trailing twelve-month revenue stands at $6,000, and it reports an employee count of 1. These financial figures indicate that Alaunos Therapeutics, Inc. is a micro-cap entity with negligible current revenue generation relative to its market valuation, suggesting it is in a pre-commercialization phase where value is derived entirely from intellectual property potential rather than operational cash flow.
Financial Health
The company reported a revenue of $6,000 for the trailing twelve months, alongside a net income of $-4,025,000 and an EBITDA of $-4,072,500. The substantial gap between the minimal revenue of $6,000 and the negative net income of $-4,025,000 reveals a cost structure heavily weighted toward research and development expenditures rather than operational efficiency. Free cash flow for the period was $-794,625, which indicates that the company is burning through cash reserves to fund its clinical programs and operational expenses. Gross margin is recorded at 0.0%, operating margin is -67883.3%, and profit margin is 0.0%, figures that collectively indicate the company is not yet profitable and that revenue does not currently cover the costs of goods sold or operations. The company holds $1.94M in cash and has N/A listed for debt, while the debt-to-equity ratio is N/A; the absence of recorded debt suggests the balance sheet relies on equity financing and cash reserves rather than leverage. The current ratio is 2.92, which indicates a strong position in short-term liquidity relative to current liabilities, allowing the firm to meet its short-term obligations with ease. Return on Equity is -145.6% and Return on Assets is -70.0%, metrics that reveal that management effectiveness in generating profit from shareholders' equity and assets is currently negative due to the significant losses incurred during the development stage.
Valuation Assessment
The trailing P/E ratio is listed as N/A because the company has not generated positive earnings, while the forward P/E is -4.97, a negative figure that implies earnings are expected to remain negative in the near term. The price-to-book ratio is 2.34, which indicates that the market values the company at a premium of 2.34 times its net asset value, reflecting the high valuation placed on its pipeline assets despite current losses. The price-to-sales ratio is 1108.47 and the EV/EBITDA is -1.16, metrics that suggest the market is valuing the company based on potential future value rather than current sales performance or earnings power. The stock's 52-week high is $6.20 and the 52-week low is $1.31, meaning the current price sits at a point where it has experienced significant volatility within this trading range. The beta value is -1.22, a negative figure that implies the stock price moves inversely to the broader market with a high degree of volatility, making it significantly more sensitive to market sentiment than a standard equity instrument.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, indicating that historical growth rates cannot be calculated due to the company's recent formation or lack of prior reporting periods. Since there are no earnings growth figures to compare against revenue, it is not possible to determine if earnings are growing faster or slower than revenue. The company does not pay a dividend, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the firm reinvests all available resources and earnings back into research and development rather than distributing income to shareholders. The overall growth and income profile is characterized by zero current revenue generation, no dividend income, and a reliance on external capital markets to fund negative growth in earnings until clinical milestones are achieved.